CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.

Autor:	Hontecillas-Prieto L; Clinical Biochemistry Service, Virgen Macarena University Hospital, University of Seville, Seville, Spain.; Department of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Virgen Macarena University Hospital, University of Seville, Seville, Spain.; Institute of Biomedicine of Seville, Virgen Macarena University Hospital, CSIC, University of Seville, Seville, Spain.; Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain., García-Domínguez DJ; Department of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Virgen Macarena University Hospital, University of Seville, Seville, Spain.; Institute of Biomedicine of Seville, Virgen Macarena University Hospital, CSIC, University of Seville, Seville, Spain., Palazón-Carrión N; Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain.; Department of Medicine, University of Seville, Seville, Spain., Martín García-Sancho A; Department of Hematology, Hospital Universitario de Salamanca, IBSAL, CIBERONC, University of Salamanca, Salamanca, Spain., Nogales-Fernández E; Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain.; Department of Medicine, University of Seville, Seville, Spain., Jiménez-Cortegana C; Department of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Virgen Macarena University Hospital, University of Seville, Seville, Spain., Sánchez-León ML; Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain., Silva-Romeiro S; Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain., Flores-Campos R; Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain., Carnicero-González F; Department of Hematology, Hospital San Pedro de Alcántara de Cáceres, Cáceres, Spain., Ríos-Herranz E; Department of Hematology, Hospital Universitario de Valme, Seville, Spain., de la Cruz-Vicente F; Department of Hematology, Hospital Universitario Virgen del Rocío, Seville, Spain., Rodríguez-García G; Department of Hematology, Hospital Universitario Virgen del Rocío, Seville, Spain., Fernández-Álvarez R; Department of Hematology, Cabueñes Hospital, Gijón, Spain., Martínez-Banaclocha N; Oncology Dept., Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain., Gumà-Padrò J; Department of Clinical Oncology, Hospital Universitari Sant Joan de Reus URV, IISPV, Reus, Spain., Gómez-Codina J; Department of Clinical Oncology, Hospital Universitario La Fé, Valencia, Spain., Salar-Silvestre A; Department of Hematology, Hospital del Mar, Barcelona, Spain., Rodríguez-Abreu D; Department of Clinical Oncology, Hospital Universitario Insular, Las Palmas de Gran Canaria, Spain., Gálvez-Carvajal L; Department of Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain., Labrador J; Department of Hematology, Research Unit, Hospital Universitario de Burgos, Burgos, Spain., Guirado-Risueño M; Department of Clinical Oncology, Hospital General Universitario de Elche, Elche, Spain., Provencio-Pulla M; Department of Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Facultad de Medicina, Universidad Autónoma de Madrid, IDIPHISA, Madrid, Spain., Sánchez-Beato M; Department of Medical Oncology, Lymphoma Research Group, Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, CIBERONC, Madrid, Spain., Marylene L; Department of Pathology, Plataforma de Estudios Histológicos, Citológicos y de Digitalización, Hospital de Tortosa Verge de la Cinta, IISPV, URV, Tortosa, Tarragona, Spain., Álvaro-Naranjo T; Department of Pathology, Hospital de Tortosa Verge de la Cinta, Catalan Institute of Health, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tortosa, Tarragona, Spain., Casanova-Espinosa M; Department of Hematology/Clinical Oncology, Hospital Costa del Sol, Marbella, Spain., Rueda-Domínguez A; Department of Hematology/Clinical Oncology, Hospital Costa del Sol, Marbella, Spain., Sánchez-Margalet V; Clinical Biochemistry Service, Virgen Macarena University Hospital, University of Seville, Seville, Spain.; Department of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Virgen Macarena University Hospital, University of Seville, Seville, Spain.; Institute of Biomedicine of Seville, Virgen Macarena University Hospital, CSIC, University of Seville, Seville, Spain., de la Cruz-Merino L; Institute of Biomedicine of Seville, Virgen Macarena University Hospital, CSIC, University of Seville, Seville, Spain.; Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain.; Department of Medicine, University of Seville, Seville, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2024 Feb 26; Vol. 15, pp. 1293931. Date of Electronic Publication: 2024 Feb 26 (Print Publication: 2024).
DOI:	10.3389/fimmu.2024.1293931
Abstrakt:	Background: Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need. Natural killer (NK) are effector cells characterized by playing an important role in antitumor immunity due to their cytotoxic capacity and a subset of circulating NK that express CD8 have a higher cytotoxic function. In this substudy of the R2-GDP-GOTEL trial, we have evaluated blood CD8+ NK cells as a predictor of treatment response and survival in relapsed/refractory (R/R) DLBCL patients. Methods: 78 patients received the R2-GDP schedule in the phase II trial. Blood samples were analyzed by flow cytometry. Statistical analyses were carried out in order to identify the prognostic potential of CD8+ NKs at baseline in R/R DLBCL patients. Results: Our results showed that the number of circulating CD8+ NKs in R/R DLBCL patients were lower than in healthy donors, and it did not change during and after treatment. Nevertheless, the level of blood CD8+ NKs at baseline was associated with complete responses in patients with R/R DLBCL. In addition, we also demonstrated that CD8+ NKs levels have potential prognostic value in terms of overall survival in R/R DLBCL patients. Conclusion: CD8+ NKs represent a new biomarker with prediction and prognosis potential to be considered in the clinical management of patients with R/R DLBCL. Clinical Trial Registration: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001620-29 EudraCT, ID:2014-001620-29. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Hontecillas-Prieto, García-Domínguez, Palazón-Carrión, Martín García-Sancho, Nogales-Fernández, Jiménez-Cortegana, Sánchez-León, Silva-Romeiro, Flores-Campos, Carnicero-González, Ríos-Herranz, de la Cruz-Vicente, Rodríguez-García, Fernández-Álvarez, Martínez-Banaclocha, Gumà-Padrò, Gómez-Codina, Salar-Silvestre, Rodríguez-Abreu, Gálvez-Carvajal, Labrador, Guirado-Risueño, Provencio-Pulla, Sánchez-Beato, Marylene, Álvaro-Naranjo, Casanova-Espinosa, Rueda-Domínguez, Sánchez-Margalet and de la Cruz-Merino.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu